1670 - Activity of Ceftolozane/Tazobactam and Comparators Against Clinical MDR and DTR Pseudomonas aeruginosa isolates – SMART United States 2018-2020

Saturday, October 22, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Co-Author(s)

FS

Fakhar Siddiqui, MD, MBA

Merck & Co., Inc.
Rahway, New Jersey, United States
KB

Karri A Bauer, PharmD

Merck Research Laboratories
Kenilworth, New Jersey, United States
CD

Charles A. DeRyke, PharmD

Director
Merck Research Laboratories
Longwood, Florida, United States
Katherine Young, M.S. (she/her/hers)

Senior Principal Scientist
Merck
Rahway, New Jersey, United States
MM

Mary Motyl, Ph.D.

Distinguished Senior Principal Scientist
Merck
Rahway, New Jersey, United States
DS

Daniel F. Sahm, PhD

VP Global Microbiology Services & Chief Scientific Officer
IHMA
Schaumburg, Illinois, United States